US Patent

US8217057 — Polymorphs of a c-MET/HGFR inhibitor

Composition of Matter · Assigned to Pfizer Inc · Expires 2029-11-06 · 3y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects polymorphs of a specific compound that inhibits the c-MET/HGFR enzyme and is useful in treating abnormal cell growth, such as cancer, in mammals.

USPTO Abstract

This invention relates to polymorphs of (R)-3-[1-(2,6-Dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to compositions including such salts and polymorphs, and to methods of using such compositions in the treatment of abnormal cell growth in mammals, especially humans.

Drugs covered by this patent

Patent Metadata

Patent number
US8217057
Jurisdiction
US
Classification
Composition of Matter
Expires
2029-11-06
Drug substance claim
Yes
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.